
AMI-1
CAS No. 20324-87-2
AMI-1( AMI-1 | AMI 1 | AMI1 | AMI-1 disodium salt. )
Catalog No. M13165 CAS No. 20324-87-2
A specific inhibitor of PRMTs (protein arginine methyltransferases), but not lysine methyltransferases.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 39 | In Stock |
![]() ![]() |
10MG | 58 | In Stock |
![]() ![]() |
25MG | 115 | In Stock |
![]() ![]() |
50MG | 170 | In Stock |
![]() ![]() |
100MG | 267 | In Stock |
![]() ![]() |
500MG | 646 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameAMI-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionA specific inhibitor of PRMTs (protein arginine methyltransferases), but not lysine methyltransferases.
-
DescriptionA specific inhibitor of PRMTs (protein arginine methyltransferases), but not lysine methyltransferases; inhibits PRMT1 and Hmt1p with IC50s of 8.81 uM and 3.03 uM respectively; increases the ratio of Bax/Bcl-2, and leads to apoptosis and loss of migratory activity in several HCC cells,decreases the expression levels of H4R3me2s; strongly inhibits HCC growth in vivo.
-
In VitroAMI-1 can inhibit the in vitro methylation reactions performed by all five recombinantly active PRMTs (PRMT1, -3, -4, and -6 and Hmt1p).AMI-1 not only inhibits type I PRMTs (PRMT1, 3, 4 and 6) but also type II PRMT5. AMI-1 specifically inhibits arginine, but not lysine, methyltransferase activity in vitro and does not compete for the AdoMet binding site. AMI-1 inhibits methylation of GFP-Npl3 and cellular proteins.AMI-1 (0.6-2.4 mM; 48-96 hours) inhibits the cell viability of sarcoma in S180 and U2OS cells in a time-dependent and dose-dependent manner in vitro.AMI-1 (1.2-2.4 mM; 48-72 hours) reduces S180 cell viability through the induction of cell apoptosis. Cell Viability Assay Cell Line:S180 cells, U2OS cells Concentration:0.6 mM, 1.2 mM, 2.4 mM Incubation Time:48 hours, 72 hours, 96 hours Result:Inhibited the cell viability.Apoptosis AnalysisCell Line:S180 cellsConcentration:1.2 mM, 2.4 mM Incubation Time:48 hours, 72 hours Result:Increased the percentages of cells undergoing apoptosis.
-
In VivoAMI-1 (0.5 mg; intratumorally; daily; for 7 days) inhibits S180 viability in vivo.AMI-1 (0.5 mg; intratumorally; daily; for 7 days) downregulates PRMT5 but does not regulate the expression of PRMT7 in a tumor xenograft model.AMI-1 (0.5 mg; intratumorally; daily; for 7 days) decreases the levels of H4R3me2s and H3R8me2s in a tumor xenograft model. Animal Model:6-7 weeks old male Kunming mice (18-22 g), with S180 cells xenograft Dosage:0.5 mg Administration:Intratumorally, daily, for 7 days Result:Decreased tumor weight.
-
SynonymsAMI-1 | AMI 1 | AMI1 | AMI-1 disodium salt.
-
PathwayChromatin/Epigenetic
-
TargetHMTase
-
RecptorPRMT1|yeastHmt1p
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number20324-87-2
-
Formula Weight548.4534
-
Molecular FormulaC21H14N2Na2O9S2
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 46 mg/mL
-
SMILESO=C(NC1=CC2=CC(S(=O)([O-])=O)=CC(O)=C2C=C1)NC3=CC4=CC(S(=O)([O-])=O)=CC(O)=C4C=C3.[Na+].[Na+]
-
Chemical Name2-Naphthalenesulfonic acid, 7,7'-(carbonyldiimino)bis[4-hydroxy-, sodium salt (1:2)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Cheng D, et al. J Biol Chem. 2004 Jun 4;279(23):23892-9.
2. Zhang B, et al. Oncotarget. 2015 Sep 8;6(26):22799-811.
3. Zhang B, et al. J Transl Med. 2015 Nov 5;13:349.
molnova catalog



related products
-
E-72
G9a inhibitor E72 (E-72) is a potent inhibitor of histone H3K9 methyltransferases G9a and G9a-like protein (GLP) with Kd of 136 nM and 164 nM.
-
DS-437
DS-437 is a potent, selective, dual inhibitor of PRMT5 and PRMT7.
-
MI-1481
MI-1481 (MI1481) is a highly potent inhibitor of the menin-MLL1 interaction with IC50 of 3.6 nM.